胃癌患者-话题@MedSci

#胃癌患者#

108篇内容 | 2486人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1769657, encodeId=51bf1e6965704, content=<a href='/topic/show?id=900b8323461' target=_blank style='color:#2F92EE;'>#胃癌患者#</a>, objectTitle=JCO：Nivolumab和Nivolumab联合Ipilimumab治疗转移性食管胃癌患者, objectType=article, longId=147192, objectId=187c14e1923f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=187c14e1923f, replyNumber=0, likeNumber=69, createdTime=2019-06-08, rootId=0, userName=huhuaidong400, userId=377c38086944, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=187c14e1923f, moduleTitle=JCO：Nivolumab和Nivolumab联合Ipilimumab治疗转移性食管胃癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=187c14e1923f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1769661, encodeId=92bd1e69661e6, content=<a href='/topic/show?id=900b8323461' target=_blank style='color:#2F92EE;'>#胃癌患者#</a>, objectTitle=J Gastroenterology：HER2变异会对HER2阳性胃癌患者接受曲妥珠单抗疗效产生影响, objectType=article, longId=153292, objectId=0cc015329201, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0cc015329201, replyNumber=0, likeNumber=64, createdTime=2019-03-29, rootId=0, userName=huhuaidong400, userId=377c38086944, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0cc015329201, moduleTitle=J Gastroenterology：HER2变异会对HER2阳性胃癌患者接受曲妥珠单抗疗效产生影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0cc015329201)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1769659, encodeId=8b7c1e6965984, content=<a href='/topic/show?id=900b8323461' target=_blank style='color:#2F92EE;'>#胃癌患者#</a>, objectTitle=GUT：HER2阳性转移性胃癌患者曲妥珠单抗耐药机制研究进展, objectType=article, longId=150583, objectId=c84815058345, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c84815058345, replyNumber=0, likeNumber=59, createdTime=2019-01-17, rootId=0, userName=huhuaidong400, userId=377c38086944, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c84815058345, moduleTitle=GUT：HER2阳性转移性胃癌患者曲妥珠单抗耐药机制研究进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c84815058345)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1769655, encodeId=7c041e696552b, content=<a href='/topic/show?id=900b8323461' target=_blank style='color:#2F92EE;'>#胃癌患者#</a>, objectTitle=Ann Oncol：HER2+胃癌患者或是拉帕替尼治疗的获益人群, objectType=article, longId=130602, objectId=f26c13060202, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f26c13060202, replyNumber=0, likeNumber=63, createdTime=2018-07-27, rootId=0, userName=huhuaidong400, userId=377c38086944, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f26c13060202, moduleTitle=Ann Oncol：HER2+胃癌患者或是拉帕替尼治疗的获益人群, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f26c13060202)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1769649, encodeId=da8d1e69649ab, content=<a href='/topic/show?id=900b8323461' target=_blank style='color:#2F92EE;'>#胃癌患者#</a>, objectTitle=救护车运送胃癌患者回家后死亡，家属追责车速太快颠簸呕吐致死！, objectType=article, longId=119860, objectId=15ac119860be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15ac119860be, replyNumber=0, likeNumber=49, createdTime=2018-03-23, rootId=0, userName=huhuaidong400, userId=377c38086944, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15ac119860be, moduleTitle=救护车运送胃癌患者回家后死亡，家属追责车速太快颠簸呕吐致死！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15ac119860be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1769647, encodeId=aebb1e69647fb, content=<a href='/topic/show?id=900b8323461' target=_blank style='color:#2F92EE;'>#胃癌患者#</a>, objectTitle=Brit J Cancer：EB病毒相关胃癌患者程序性死亡受体表达亚型与预后, objectType=article, longId=118980, objectId=0f3811898072, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f3811898072, replyNumber=0, likeNumber=64, createdTime=2018-10-02, rootId=0, userName=huhuaidong400, userId=377c38086944, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f3811898072, moduleTitle=Brit J Cancer：EB病毒相关胃癌患者程序性死亡受体表达亚型与预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f3811898072)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1769654, encodeId=80461e69654d4, content=<a href='/topic/show?id=900b8323461' target=_blank style='color:#2F92EE;'>#胃癌患者#</a>, objectTitle=2018 ASCO-GI：RhoA调控通路突变对胃癌患者生存的影响, objectType=article, longId=127766, objectId=d33412e76652, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d33412e76652, replyNumber=0, likeNumber=60, createdTime=2018-05-23, rootId=0, userName=huhuaidong400, userId=377c38086944, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d33412e76652, moduleTitle=2018 ASCO-GI：RhoA调控通路突变对胃癌患者生存的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d33412e76652)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1769653, encodeId=c1171e696537a, content=<a href='/topic/show?id=900b8323461' target=_blank style='color:#2F92EE;'>#胃癌患者#</a>, objectTitle=这位晚期胃癌患者生存超过了10年, objectType=article, longId=126953, objectId=819d1269535e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=819d1269535e, replyNumber=0, likeNumber=75, createdTime=2018-11-24, rootId=0, userName=huhuaidong400, userId=377c38086944, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=819d1269535e, moduleTitle=这位晚期胃癌患者生存超过了10年, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=819d1269535e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1769645, encodeId=3dd31e69645f6, content=<a href='/topic/show?id=900b8323461' target=_blank style='color:#2F92EE;'>#胃癌患者#</a>, objectTitle=Cancer Sci：肿瘤和血清中的LRG1或可用于胃癌患者的预后分析, objectType=article, longId=115921, objectId=ee7111592197, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee7111592197, replyNumber=0, likeNumber=55, createdTime=2018-07-06, rootId=0, userName=huhuaidong400, userId=377c38086944, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee7111592197, moduleTitle=Cancer Sci：肿瘤和血清中的LRG1或可用于胃癌患者的预后分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee7111592197)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1769644, encodeId=7e011e6964448, content=<a href='/topic/show?id=900b8323461' target=_blank style='color:#2F92EE;'>#胃癌患者#</a>, objectTitle=JAMA Surg：胃癌患者辅助化疗能否获益？不妨试一下这个生存预测模型, objectType=article, longId=111136, objectId=2297111136e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2297111136e8, replyNumber=0, likeNumber=60, createdTime=2017-12-10, rootId=0, userName=huhuaidong400, userId=377c38086944, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2297111136e8, moduleTitle=JAMA Surg：胃癌患者辅助化疗能否获益？不妨试一下这个生存预测模型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2297111136e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1769652, encodeId=3f4b1e696522d, content=<a href='/topic/show?id=900b8323461' target=_blank style='color:#2F92EE;'>#胃癌患者#</a>, objectTitle=Lancet Oncol：奥拉帕尼+紫杉醇亚洲晚期胃癌患者的理想选择？, objectType=article, longId=125694, objectId=45f5125694ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45f5125694ca, replyNumber=0, likeNumber=63, createdTime=2018-04-09, rootId=0, userName=huhuaidong400, userId=377c38086944, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45f5125694ca, moduleTitle=Lancet Oncol：奥拉帕尼+紫杉醇亚洲晚期胃癌患者的理想选择？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45f5125694ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1769651, encodeId=3bb81e69651e0, content=<a href='/topic/show?id=900b8323461' target=_blank style='color:#2F92EE;'>#胃癌患者#</a>, objectTitle=JAMA SURG：MGMT蛋白表达与Ⅱ或Ⅲ期胃癌患者预后及辅助化疗获益的关系, objectType=article, longId=121117, objectId=a7b512111e87, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7b512111e87, replyNumber=0, likeNumber=55, createdTime=2018-01-09, rootId=0, userName=huhuaidong400, userId=377c38086944, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7b512111e87, moduleTitle=JAMA SURG：MGMT蛋白表达与Ⅱ或Ⅲ期胃癌患者预后及辅助化疗获益的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7b512111e87)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1769643, encodeId=e6c91e69643e4, content=<a href='/topic/show?id=900b8323461' target=_blank style='color:#2F92EE;'>#胃癌患者#</a>, objectTitle=Crit Rev Oncol Hematol：转移性/进展期胃癌患者疾病进展后，是否行三线全身治疗？, objectType=article, longId=107300, objectId=b3d610e300a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3d610e300a0, replyNumber=0, likeNumber=55, createdTime=2017-10-12, rootId=0, userName=huhuaidong400, userId=377c38086944, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3d610e300a0, moduleTitle=Crit Rev Oncol Hematol：转移性/进展期胃癌患者疾病进展后，是否行三线全身治疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3d610e300a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1769648, encodeId=ab811e6964839, content=<a href='/topic/show?id=900b8323461' target=_blank style='color:#2F92EE;'>#胃癌患者#</a>, objectTitle=Lancet ONCOL：奥拉帕尼联合紫杉醇治疗一线治疗后进展的晚期胃癌患者, objectType=article, longId=119081, objectId=b0e911908184, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0e911908184, replyNumber=0, likeNumber=74, createdTime=2018-03-13, rootId=0, userName=huhuaidong400, userId=377c38086944, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0e911908184, moduleTitle=Lancet ONCOL：奥拉帕尼联合紫杉醇治疗一线治疗后进展的晚期胃癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b0e911908184)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1769646, encodeId=a2661e6964651, content=<a href='/topic/show?id=900b8323461' target=_blank style='color:#2F92EE;'>#胃癌患者#</a>, objectTitle=SCI REP：中性粒细胞与淋巴细胞比变化值是一个更好的胃癌患者生存预测指标！, objectType=article, longId=117604, objectId=0bae11e60435, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0bae11e60435, replyNumber=0, likeNumber=57, createdTime=2018-08-13, rootId=0, userName=huhuaidong400, userId=377c38086944, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0bae11e60435, moduleTitle=SCI REP：中性粒细胞与淋巴细胞比变化值是一个更好的胃癌患者生存预测指标！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0bae11e60435)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1769642, encodeId=833e1e696421d, content=<a href='/topic/show?id=900b8323461' target=_blank style='color:#2F92EE;'>#胃癌患者#</a>, objectTitle=JAMA Surg：辅助化疗与胃癌患者生存时间的关系, objectType=article, longId=107205, objectId=63a810e2056d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63a810e2056d, replyNumber=0, likeNumber=86, createdTime=2017-12-19, rootId=0, userName=huhuaidong400, userId=377c38086944, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63a810e2056d, moduleTitle=JAMA Surg：辅助化疗与胃癌患者生存时间的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63a810e2056d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1769650, encodeId=e2ee1e69650ae, content=<a href='/topic/show?id=900b8323461' target=_blank style='color:#2F92EE;'>#胃癌患者#</a>, objectTitle=Gastroenterology：低剂量阿司匹林不能降低食管癌或胃癌患者死亡风险, objectType=article, longId=121065, objectId=7036121065e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7036121065e7, replyNumber=0, likeNumber=75, createdTime=2018-09-04, rootId=0, userName=huhuaidong400, userId=377c38086944, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7036121065e7, moduleTitle=Gastroenterology：低剂量阿司匹林不能降低食管癌或胃癌患者死亡风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7036121065e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1769641, encodeId=59c71e6964187, content=<a href='/topic/show?id=900b8323461' target=_blank style='color:#2F92EE;'>#胃癌患者#</a>, objectTitle=The Lancet Oncology：曲妥珠单抗不能提高HER2阳性晚期胃癌患者的生存率, objectType=article, longId=93205, objectId=fef993205fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fef993205fc, replyNumber=0, likeNumber=40, createdTime=2017-04-11, rootId=0, userName=huhuaidong400, userId=377c38086944, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fef993205fc, moduleTitle=The Lancet Oncology：曲妥珠单抗不能提高HER2阳性晚期胃癌患者的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fef993205fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1769640, encodeId=878c1e6964005, content=<a href='/topic/show?id=900b8323461' target=_blank style='color:#2F92EE;'>#胃癌患者#</a>, objectTitle=Ann Surg：胃癌患者RTK和DSS基因拷贝数状态研究, objectType=article, longId=81448, objectId=90f18144876, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90f18144876, replyNumber=0, likeNumber=67, createdTime=2017-04-26, rootId=0, userName=huhuaidong400, userId=377c38086944, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90f18144876, moduleTitle=Ann Surg：胃癌患者RTK和DSS基因拷贝数状态研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90f18144876)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1769639, encodeId=87ef1e69639a0, content=<a href='/topic/show?id=900b8323461' target=_blank style='color:#2F92EE;'>#胃癌患者#</a>, objectTitle=ESMO 2016：奥拉帕尼能否改善胃癌患者的总生存期？（GOLD试验）, objectType=article, longId=79623, objectId=aa97e962349, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa97e962349, replyNumber=0, likeNumber=54, createdTime=2017-01-19, rootId=0, userName=huhuaidong400, userId=377c38086944, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa97e962349, moduleTitle=ESMO 2016：奥拉帕尼能否改善胃癌患者的总生存期？（GOLD试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa97e962349)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

胃癌患者

2020-05-29

huhuaidong400 (审核中...)

前往app查看评论内容

#胃癌患者#

JCO：Nivolumab和Nivolumab联合Ipilimumab治疗转移性食管胃癌患者

2019-06-08

huhuaidong400 (审核中...)

前往app查看评论内容

#胃癌患者#

J Gastroenterology：HER2变异会对HER2阳性胃癌患者接受曲妥珠单抗疗效产生影响

2019-03-29

huhuaidong400 (审核中...)

前往app查看评论内容

#胃癌患者#

GUT：HER2阳性转移性胃癌患者曲妥珠单抗耐药机制研究进展

2019-01-17

huhuaidong400 (审核中...)

前往app查看评论内容

#胃癌患者#

Ann Oncol：HER2+胃癌患者或是拉帕替尼治疗的获益人群

2018-07-27

huhuaidong400 (审核中...)

前往app查看评论内容

#胃癌患者#

救护车运送胃癌患者回家后死亡，家属追责车速太快颠簸呕吐致死！

2018-03-23

huhuaidong400 (审核中...)

前往app查看评论内容

#胃癌患者#

Brit J Cancer：EB病毒相关胃癌患者程序性死亡受体表达亚型与预后

2018-10-02

huhuaidong400 (审核中...)

前往app查看评论内容

#胃癌患者#

2018 ASCO-GI：RhoA调控通路突变对胃癌患者生存的影响

2018-05-23

huhuaidong400 (审核中...)

前往app查看评论内容

#胃癌患者#

这位晚期胃癌患者生存超过了10年

2018-11-24

huhuaidong400 (审核中...)

前往app查看评论内容

#胃癌患者#

Cancer Sci：肿瘤和血清中的LRG1或可用于胃癌患者的预后分析

2018-07-06

huhuaidong400 (审核中...)

前往app查看评论内容

#胃癌患者#

JAMA Surg：胃癌患者辅助化疗能否获益？不妨试一下这个生存预测模型

2017-12-10

huhuaidong400 (审核中...)

前往app查看评论内容

#胃癌患者#

Lancet Oncol：奥拉帕尼+紫杉醇亚洲晚期胃癌患者的理想选择？

2018-04-09

huhuaidong400 (审核中...)

前往app查看评论内容

#胃癌患者#

JAMA SURG：MGMT蛋白表达与Ⅱ或Ⅲ期胃癌患者预后及辅助化疗获益的关系

2018-01-09

huhuaidong400 (审核中...)

前往app查看评论内容

#胃癌患者#

Crit Rev Oncol Hematol：转移性/进展期胃癌患者疾病进展后，是否行三线全身治疗？

2017-10-12

huhuaidong400 (审核中...)

前往app查看评论内容

#胃癌患者#

Lancet ONCOL：奥拉帕尼联合紫杉醇治疗一线治疗后进展的晚期胃癌患者

2018-03-13

huhuaidong400 (审核中...)

前往app查看评论内容

#胃癌患者#

SCI REP：中性粒细胞与淋巴细胞比变化值是一个更好的胃癌患者生存预测指标！

2018-08-13

huhuaidong400 (审核中...)

前往app查看评论内容

#胃癌患者#

JAMA Surg：辅助化疗与胃癌患者生存时间的关系

2017-12-19

huhuaidong400 (审核中...)

前往app查看评论内容

#胃癌患者#

Gastroenterology：低剂量阿司匹林不能降低食管癌或胃癌患者死亡风险

2018-09-04

huhuaidong400 (审核中...)

前往app查看评论内容

#胃癌患者#

The Lancet Oncology：曲妥珠单抗不能提高HER2阳性晚期胃癌患者的生存率

2017-04-11

huhuaidong400 (审核中...)

前往app查看评论内容

#胃癌患者#

Ann Surg：胃癌患者RTK和DSS基因拷贝数状态研究

2017-04-26

huhuaidong400 (审核中...)

前往app查看评论内容

#胃癌患者#

ESMO 2016：奥拉帕尼能否改善胃癌患者的总生存期？（GOLD试验）

2017-01-19

科室
- - 订阅+
  - 更多科室
工具
服务